CN100563690C - A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc - Google Patents

A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc Download PDF

Info

Publication number
CN100563690C
CN100563690C CNB2006100170493A CN200610017049A CN100563690C CN 100563690 C CN100563690 C CN 100563690C CN B2006100170493 A CNB2006100170493 A CN B2006100170493A CN 200610017049 A CN200610017049 A CN 200610017049A CN 100563690 C CN100563690 C CN 100563690C
Authority
CN
China
Prior art keywords
radix
medicine
parts
wind
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100170493A
Other languages
Chinese (zh)
Other versions
CN101108226A (en
Inventor
金立新
Original Assignee
金立新
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 金立新 filed Critical 金立新
Priority to CNB2006100170493A priority Critical patent/CN100563690C/en
Publication of CN101108226A publication Critical patent/CN101108226A/en
Application granted granted Critical
Publication of CN100563690C publication Critical patent/CN100563690C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention relates to a kind of medicine that is used for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc, the trade name of this medicine is that " anemofrigid-damp arthralgia is logical to dissipate " and " anemofrigid-damp arthralgia leads to capsule for eliminating " this medicine are the conventional Chinese medicine dosage forms that is prepared from by Herba Ephedrae, river Niu Xi, Rhizoma Homalomenae, fructus lycii, Radix Saposhnikoviae, Rhizoma Et Radix Notopterygii, Semen Strychni, charred Cortex Eucommiae, Ramulus Cinnamomi, Olibanum, Myrrha, Fructus Chaenomelis, Cortex schizophragmatis integrifolii radicis, Radix Angelicae Sinensis, Radix Glycyrrhizae, Radix Angelicae Pubescentis, the Radix Paeoniae Alba, has the good curing effect for rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc.Medicine of the present invention is compared with similar medicine, this medicine can not only take stopgap measures, can also effect a permanent cure, reach the purpose for the treatment of both the principal and the secondary aspects of a disease at the same time,, compare with chemicals through patient's determined curative effect, the economy of clinical treatment observation to rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc, not only curative effect is big, and toxic and side effects is little, needs only the patient of medication on request, significantly reduces relapse rate and disability rate.

Description

A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc
Technical field
The present invention relates to a kind of Chinese patent medicine, belong to the field of Chinese medicines, a kind of specifically medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc.
Background technology
Rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc belong to the Chinese medicine wind-cold damp pathogen and hinder, be one of commonly encountered diseases and frequently-occurring disease clinically, rheumatism, the rheumatoid pilosity is crowd more than 15 years old, puerperal exposure to wind is many morbidity in more than 20 year old, hyperosteogeny mostly occurs at middle-aged and elderly people more than more than 40 year old, and the trend of oriented younger development, its pathogeny is to replenish deficiency or lose relevant too much because of present human calcium ion, prolapse of lumbar intervertebral disc mostly occurs the patient more than 20 years old, the trend of increasing is arranged now, its factor may be in the rare pass of mankind's activity amount, but the waist ligament why the slacken reason is not still understood, remain further research.
More than all diseases once the morbidity, all can influence and work and take care of oneself, lifelong deformity can appear in the delay treatment person, more to the medicine of above all sick treatments at present, doctor trained in Western medicine is treated with hormone and analgesic, and hormone is bigger to the human body destructiveness, and forms dependence, some drug price costliness on the market does not reach the purpose for the treatment of both the principal and secondary aspects of a disease.Therefore the present invention is the medicine that a kind for the treatment of both the principal and secondary aspects of a disease of research is treated above-mentioned all diseases, and this also is pressing for of current medical circle.
Summary of the invention
The objective of the invention is to overcome above-mentioned the deficiencies in the prior art, a kind of instant effect is provided, evident in efficacy, toxic and side effects is little, the medicine of treatment rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and the disease of proplapse of lumbar intervertebral disc for the treatment of both the principal and the secondary aspects of a disease at the same time.
Rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc, more than all sick traditional Chinese medical science " element is asked, numbness opinion " point out " wind, cold, wet three gas are assorted extremely, close and are numbness, its migratory BI-syndrome caused mainly by pathogenic wind; BI-syndrome caused mainly by pathogenic cold being called painful BI; the dampness victor be all numbness " wind, tremble with fear, damp lingers in muscles and bones, then pain unbearably, disease is deeply with the passing of time, it is puckery that battalion defends trip, skin is not sought, and then apathetic, pathogenic factor is deep." numbness opinion " also think numbness to result from the dietetic life environment relevant, can invade the five internal organs six abdomens, modern medicine thinks, rheumatism, rheumatoid, is to cause allergy after being infected by group B streptococcus, it is consistent can extensively invading organ such as heart.The prolapse of lumbar intervertebral disc and the hyperosteogeny traditional Chinese medical science say it is to cross victory by dampness to be hindered in addition, and the numbness of " numbness opinion " indication is that disease deeply with the passing of time by wind, cold, wet all gas cut human bodies, it is puckery that battalion defends trip, and pathogenic factor is deep, eliminating to treat the excess syndrome, must drive it, can answer also, so in treatment, with wind dispelling cold expelling, wet eliminating impediment, collateral dredging relieves the pain, the method of strengthening kidney and tonifying bone, thus select for use Herba Ephedrae, Cortex schizophragmatis integrifolii radicis, Fructus Chaenomelis, Radix Saposhnikoviae, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Rhizoma Homalomenae that the wind dispelling cold expelling is all arranged, the effect of warm eliminating impediment.In addition, Ramulus Cinnamomi, Semen Strychni, Olibanum, Myrrha can loose and separate detumescence, removing obstruction in the collateral to relieve pain, river Niu Xi, charred Cortex Eucommiae, fructus lycii, and all the energy invigorating the liver and kidney reaches the purpose of reinforcing waist and strengthening bone.Moreover Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Glycyrrhizae 5 usefulness play anxious pain relieving, the mediation property of medicine, double cold coagulation and the disharmony of nutrient QI with defensive QI etc. controlled.
Said medicine is share, can effectively reach, wind dispelling cold expelling, wet eliminating impediment, activating collaterals to relieve pain, strengthening kidney and tonifying bone, institute so that all clinically condition of illness alleviate or disappear.Effective percentage is very high in treatment.
The object of the present invention is achieved like this, the medicament that the present invention is made by the following weight proportion raw material:
Herba Ephedrae 30-65 part river cattle sunset 5-15 part Rhizoma Homalomenae 5-10 part fructus lycii 5-10 part
Radix Saposhnikoviae 5-10 part Rhizoma Et Radix Notopterygii 5-10 part Semen Strychni 5-12 part charred Cortex Eucommiae 5-15 part
Ramulus Cinnamomi 5-15 part Olibanum 5-15 part Myrrha 5-15 part Fructus Chaenomelis 20-25 part
Cortex schizophragmatis integrifolii radicis 20-25 part Radix Angelicae Sinensis 5-15 part Radix Glycyrrhizae 5-15 part Radix Angelicae Pubescentis 5-10 part
Radix Paeoniae Alba 5-10 part
The preferable amount proportioning of drug regimen of the present invention is:
Herba Ephedrae 30-65 part river cattle sunset 7-10 part Rhizoma Homalomenae 7-10 part fructus lycii 8-15 part
Radix Saposhnikoviae 7-10 part Rhizoma Et Radix Notopterygii 7-10 part Semen Strychni 8-12 part charred Cortex Eucommiae 8-15 part
Ramulus Cinnamomi 8-15 part Olibanum 8-15 part Myrrha 8-15 part Fructus Chaenomelis 20-25 part
Cortex schizophragmatis integrifolii radicis 20-25 part Radix Angelicae Sinensis 8-10 part Radix Glycyrrhizae 8-10 part Radix Angelicae Pubescentis 7-10 part
Radix Paeoniae Alba 7-10 part
The optimum amount proportioning of pharmaceutical composition of the present invention is:
10 parts of 10 parts of Radix Saposhnikoviaes of Herba Ephedrae 10 parts of fructus lyciis of 65 parts of river cattle sunset, 10 parts of Rhizoma Homalomenaes
15 parts of 10 parts of Olibanums of 15 parts of Ramulus Cinnamomi of 12 parts of charred Cortex Eucommiaes of 10 parts of Semen Strychnis of Rhizoma Et Radix Notopterygii
15 parts in 15 portions of Radix Glycyrrhizaes of 25 parts of Radix Angelicae Sinensis of 25 parts of Cortex schizophragmatis integrifolii radicis of 15 portions of Fructus Chaenomeliss of Myrrha
10 parts of 10 portions of Radix Paeoniae Albas of Radix Angelicae Pubescentis
Pharmaceutical composition of the present invention can be prepared from any pharmaceutical preparation that is suitable for using clinically according to the process of Chinese medicine preparation of routine, as tablet, powder, capsule, pill etc.
Preferred dosage form of the present invention is powder and capsule, and its preparation method is:
(1) earlier 120 mesh sieves was pulverized in Semen Strychni parch oven dry.
(2) 120 mesh sieves were pulverized in river Niu Xi, Rhizoma Homalomenae, fructus lycii, Radix Saposhnikoviae, charred Cortex Eucommiae, Ramulus Cinnamomi, Olibanum, Myrrha, Radix Angelicae Sinensis, Radix Glycyrrhizae oven dry.
(3) the part composition of medicine that will not pulverize again decocts.
(4) medicine of pulverizing and the medicinal liquid of decoction are stirred, dry, pulverize.
(5) reuse 120 mesh sieves sieve and stir, subpackage or incapsulate, and every bag or grain weight reach 0.5 gram, are equipped with clothes.
Drug use method of the present invention is:
1, treatment: the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc, from making a definite diagnosis day, taking " anemofrigid-damp arthralgia is logical to dissipate or capsule " every day takes 3 every day, at every turn at 2.0 grams, begin after serveing on 10 to take effect, then begin to obey the course of treatment, treatment rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny 3-4 can cure a course of treatment, the prolapse of lumbar intervertebral disc patient must not obey the course of treatment.
2, rehabilitation: after the patient of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc takes medicine, transference cure or obviously alleviate, the person that do not return to one's perfect health this moment please hold on and take medicine.
Rheumatism, rheumatoid, puerperal exposure to wind patient transference cure, chemical examination resists " 0 " and rheumatoid factor negative every other month, continuous 3 complete healing.Prolapse of lumbar intervertebral disc patient clinical symptoms and the equal feminine gender of sign after taking medicine are carried out comings and goings is not all had overslaugh, and the CT report is normal to be rehabilitation.
Medicine of the present invention is compared with similar Chinese medicine, has the following advantages:
(1), when clinical drug of the present invention is used for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc, can reaches really and drive district's cold expelling, the effect of wet eliminating impediment, removing obstruction in the collateral to relieve pain, strengthening kidney and tonifying bone.Clinical proof not only symptom is eliminated soon, can also soften bony spur, and reduce relapse rate and disability rate that above-mentioned all kinds of disease causes significantly.
(2), medicine of the present invention compares with similar Chinese medicine, this medicine can not only take stopgap measures and can also effect a permanent cure, and reaches the purpose for the treatment of both the principal and secondary aspects of a disease.This medicine is taking convenience not only, and instant effect.
(3), compare, not only curative effect is big, and except that not containing the hormone, this medicine does not have the property of accumulating, no drug resistance and addiction, advantage such as toxic and side effects is few with chemicals.
For showing the therapeutic effect of the present invention to rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc, 620 routine rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc patient are divided into two groups contrast treatment, two groups of ages, sex and diseases all adopt random sampling pattern, wherein 620 examples are organized in treatment, and matched group 100 routine clinical development standards are according to the above-mentioned all sick efficacy assessment standard evaluation of passing through about rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc research association for Chinese Medical Association's whole nation traditional Chinese medical science (concrete evaluation criteria is simple).
The treatment group adopts logical dissipation of anemofrigid-damp arthralgia and capsule, and matched group adopts hormone and active star, takes through the clinical statement oral methods, and clinical practice shows effective percentage apparently higher than matched group, and P value<0.05 proves notable difference (seeing table 1 for details).
Table 1 smelting treatment group and the comparison of photograph group curative effect (X ± S)
The example number Produce effects Effectively Invalid Total effective rate
N N % N % N % N % The D value
The treatment group 620 486 78.2 125 20.1 7 1.1 611 98.3 <0.05
Matched group 100 32 32 25 25 23 23 57 57
In 620 example treatment cases, wherein the man suffers from 322 examples, and the woman suffers from 398 examples, and men and women's ratio is nonsensical.
In 620 example treatment cases, the age distribution situation is maximum 82 years old, minimal ages 13 years old, clinical trial certificate, anemofrigid-damp arthralgia is logical to dissipate and capsule, all effective to each age group patient, we carry out tracing observation to the convalescent of treatment group and matched group simultaneously, observe its relapse rate, the result shows, treatment group and matched group are widely different, with 1 year be the contrast time, matched group is after treatment, the patient of recurrence is higher than the treatment group, and there is notable difference (seeing table 2 for details) P value<0.05
After being treated, table 2, treatment group and matched group recur contrast table again
The example number Produce effects Effectively Recurrence Total relapse rate
N N N N N % The P value
The treatment group 611 486 125 7 5 0.8 <0.05
Matched group 57 32 25 9 9 16
The specific embodiment
Earlier with the Semen Strychni parch, again 10 parts of the river cattle sunset in the composition of medicine, 10 parts of Rhizoma Homalomenaes, 10 parts of fructus lyciis, Radix Saposhnikoviae 10 minutes, 15 parts of charred Cortex Eucommiaes, 10 parts of Ramulus Cinnamomi, 15 parts of Olibanums, 15 parts of Myrrhas, 15 parts of Radix Angelicae Sinensis, 10 parts of the Radix Paeoniae Albas, Radix Glycyrrhizae are dried pulverizing for 15 parts, with 120 mesh sieves medicine being sieved then stirs, stand-by.Other remaining set composite medicine adds water and soaked 1 hour for 1500 milliliters, and the back decocted 1 hour, after taking out medicinal liquid, add 1000 milliliters in water again, decoct again about 30 minutes, carrying out twice same water of usefulness and time continuously decocts, and decocts medicinal liquids with three times and leaves standstill sedimentation and filtration, reheat is concentrated into 500 milliliters, the composition of medicine of stand-by pulverizing is stirred, and oven dry is pulverized once more, and then get 120 mesh sieves, all composition of medicine are sieved to stir.The medicine subpackage of pulverizing or incapsulate, every bag or grain weigh 0.5 gram, every day three times, each 2.0 grams.

Claims (5)

1, a kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc is characterized in that: it is the medicament of being made by the following weight proportion raw material:
Herba Ephedrae 30-65 part river cattle sunset 5-15 part Rhizoma Homalomenae 5-10 part fructus lycii 5-10 part
Radix Saposhnikoviae 5-10 part Rhizoma Et Radix Notopterygii 5-10 part Semen Strychni 5-12 part charred Cortex Eucommiae 5-15 part
Ramulus Cinnamomi 5-10 part Olibanum 5-15 part Myrrha 5-15 part Fructus Chaenomelis 20-25 part
Cortex schizophragmatis integrifolii radicis 20-25 part Radix Angelicae Sinensis 5-15 part Radix Glycyrrhizae 5-15 part Radix Angelicae Pubescentis 5-10 part
Radix Paeoniae Alba 5-10 part.
2, require 1 described a kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc according to letter of authorization, it is characterized in that: wherein each proportion of raw materials is:
Herba Ephedrae 30-65 part river cattle sunset 7-10 part Rhizoma Homalomenae 7-10 part fructus lycii 8-10 part
Radix Saposhnikoviae 7-10 part Rhizoma Et Radix Notopterygii 7-10 part Semen Strychni 8-12 part charred Cortex Eucommiae 8-15 part
Ramulus Cinnamomi 8-15 part Olibanum 8-15 part Myrrha 8-15 part Fructus Chaenomelis 20-25 part
Cortex schizophragmatis integrifolii radicis 20-25 part Radix Angelicae Sinensis 8-10 part Radix Glycyrrhizae 8-10 part Radix Angelicae Pubescentis 7-10 part
Radix Paeoniae Alba 7-10 part.
3, require 1 described a kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc according to letter of authorization, it is characterized in that: wherein each proportion of raw materials is:
10 parts of 10 parts of Radix Saposhnikoviaes of Herba Ephedrae 10 parts of fructus lyciis of 65 parts of river cattle sunset, 10 parts of Rhizoma Homalomenaes
15 parts of 10 parts of Olibanums of 15 parts of Ramulus Cinnamomi of 12 parts of charred Cortex Eucommiaes of 10 parts of Semen Strychnis of Rhizoma Et Radix Notopterygii
15 parts in 15 portions of Radix Glycyrrhizaes of 25 parts of Radix Angelicae Sinensis of 25 parts of Cortex schizophragmatis integrifolii radicis of 15 portions of Fructus Chaenomeliss of Myrrha
10 parts of 10 portions of Radix Paeoniae Albas of Radix Angelicae Pubescentis.
4, require 1 or 2 or 3 described a kind of medicines for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc according to letter of authorization, it is characterized in that: the dosage form of this medicine is powder, capsule preparations.
5, require 4 described a kind of preparation methoies for the treatment of the medicine of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and prolapse of lumbar intervertebral disc according to letter of authorization, it is characterized in that: the preparation method of described powder and capsule preparations is:
(1) earlier 120 mesh sieves was pulverized in Semen Strychni parch oven dry;
(2) 120 mesh sieves were pulverized in river Niu Xi, Rhizoma Homalomenae, fructus lycii, Radix Saposhnikoviae, charred Cortex Eucommiae, Ramulus Cinnamomi, Olibanum, Myrrha, Radix Angelicae Sinensis, Radix Glycyrrhizae oven dry;
(3) the part composition of medicine that will not pulverize again decocts;
(4) medicine of pulverizing and the medicinal liquid of decoction are stirred, dry, pulverize;
(5) reuse 120 mesh sieves sieve and stir, subpackage or incapsulate, and every bag or grain weight reach 0.5 gram, are equipped with clothes.
CNB2006100170493A 2006-07-20 2006-07-20 A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc Expired - Fee Related CN100563690C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100170493A CN100563690C (en) 2006-07-20 2006-07-20 A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100170493A CN100563690C (en) 2006-07-20 2006-07-20 A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc

Publications (2)

Publication Number Publication Date
CN101108226A CN101108226A (en) 2008-01-23
CN100563690C true CN100563690C (en) 2009-12-02

Family

ID=39040614

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100170493A Expired - Fee Related CN100563690C (en) 2006-07-20 2006-07-20 A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc

Country Status (1)

Country Link
CN (1) CN100563690C (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101816729A (en) * 2010-03-03 2010-09-01 鲍旭刚 Medicament for treating arthritis and preparation method thereof
CN102526261A (en) * 2012-02-21 2012-07-04 简福川 Chinese medicine for treating lumbar vertebra osteoproliferation
CN102579625B (en) * 2012-03-07 2013-07-31 南京同仁堂药业有限责任公司 Preparation method of Chinese medicinal dropping pills for treating rheumatoid arthritis
CN102614388A (en) * 2012-04-25 2012-08-01 董宜忠 Chinese medicinal wine for treating rheumatoid arthritis and preparation method thereof
CN102935154A (en) * 2012-12-06 2013-02-20 冷凤珍 Traditional Chinese medicinal preparation for treating lumbar disc herniation
CN103623249A (en) * 2013-12-05 2014-03-12 韩友群 Traditional Chinese medicine oral preparation for treating orthopedic disorders and preparation method thereof
CN104069271B (en) * 2014-07-22 2017-08-15 曹共和 A kind of medicine for treating hyperosteogeny
CN104208290A (en) * 2014-08-22 2014-12-17 赵红丽 Composition for treating postpartum rheumatism by mud moxibustion
CN104383166A (en) * 2014-10-27 2015-03-04 杨晓军 Medicine for treating rheumatic lumbocrural pains and preparation method thereof
CN104587105A (en) * 2015-01-30 2015-05-06 刘雨秋 Traditional Chinese medicine for treating rheumatoid arthritis and rheumatoid diseases
CN109419954A (en) * 2017-09-05 2019-03-05 辽宁泓新科技成果转化服务有限公司 A kind of ointment and its device for treating prolapse of lumbar intervertebral disc
CN112168908A (en) * 2019-07-05 2021-01-05 黄胜昔 Traditional Chinese medicine for treating wind-cold-dampness arthralgia and tendon and vessel discomfort and preparation method thereof
CN113082081A (en) * 2020-01-08 2021-07-09 韩长序 External medicinal liquor for lumbar intervertebral disc
CN111467396A (en) * 2020-04-30 2020-07-31 邵俊信 Oral capsule for treating ostealgia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
中华人民共和国卫生部药品标准中药成方制剂. 中华人民共和国卫生部药典委员会,135. 1991
中华人民共和国卫生部药品标准中药成方制剂. 中华人民共和国卫生部药典委员会,135. 1991 *

Also Published As

Publication number Publication date
CN101108226A (en) 2008-01-23

Similar Documents

Publication Publication Date Title
CN100563690C (en) A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc
CN102614440B (en) Multi-herb antibacterial liquid
CN101757569A (en) Traditional Chinese medicine composition for treating cerebral thrombosis and cerebral infarction and preparation method thereof
CN100376229C (en) A medicinal wine for treating rheumatic and rheumatoid disease
CN1839941A (en) Chinese prepared medicine for treating bone pain
CN101810835A (en) Chinese medicinal composition for treating purpura and preparation method thereof
CN103585378A (en) Traditional Chinese medicine composition for treating female infertility and preparation method thereof
CN104398982A (en) Traditional Chinese medicine composition for treating traumatic injury and joint pain and swelling
CN101181568B (en) Traditional chinese medicine preparation for curing osteoproliferation as well as arthrosis ache
CN105362491A (en) External-use medicine for treating cervical vertebra hyperosteogeny
CN102008610B (en) Traditional Chinese medicine composition for curing hyperosteogeny
CN1390585A (en) Chinese medicine for detoxication purpose and its preparing process
CN102579982A (en) Externally-applied patch of for local point to treat gynecologic pelvic inflammatory disease and preparation method thereof
CN101912567B (en) Chinese medicinal prescription for treating chronic myocarditis
CN101829315B (en) Traditional Chinese medicine composition for treating headache during menstruation and preparation method thereof
CN1843421A (en) Rheumatoid disease treating medicine
CN102949507B (en) Traditional Chinese medicine lotion for treating lumbocrural pain and preparation method thereof
CN105943644B (en) A kind of Chinese medicine moxibustion composition and its preparation method and application for lumbar muscle strain
CN101708300A (en) Medicinal composition for treating scrofula, hyperplasia of mammary glands and benign lymphadenoma
CN101658635B (en) Chinese medical preparation for treating burn and scald and preparation method
CN101361868B (en) Traditional Chinese medicine combination for treating rheumatism
CN100411672C (en) A medicinal composition for treatment of psoriasis
CN102764325B (en) Chinese medicinal composition for dispelling rheumatism and relieving pain
CN102018765A (en) Traditional Chinese medicine for treating diabetic acromelic gangrene
CN106389557B (en) A kind of Chinese medicine composition and its preparation method and application for Chinese medicine moxibustion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091202

Termination date: 20130720